Cargando…

Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)

BACKGROUND: The durability of immune responses to COVID-19 vaccines among older people living with HIV (PWH) is clinically important. METHODS: We aimed to assess vaccine-induced humoral immunity and durability in older PWH (≥ 55 years, n = 26) over 6 months (post-initial BNT162b2 series). A secondar...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuan, Jessica J., Zapata, Heidi, Barakat, Lydia, Andrews, Laurie, Behnegar, Anousheh, Kim, Yee Won, Kayani, Jehanzeb, Mutic, Suzana, Ryall, Linda, Turcotte, Barbara, Critch-Gilfillan, Terese, Zhao, Min, Salahuddin, Syim, Gupta, Shaili, Sutton, Richard, Friedland, Gerald, Emu, Brinda, Ogbuagu, Onyema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491266/
https://www.ncbi.nlm.nih.gov/pubmed/36131232
http://dx.doi.org/10.1186/s12879-022-07737-0
_version_ 1784793246417813504
author Tuan, Jessica J.
Zapata, Heidi
Barakat, Lydia
Andrews, Laurie
Behnegar, Anousheh
Kim, Yee Won
Kayani, Jehanzeb
Mutic, Suzana
Ryall, Linda
Turcotte, Barbara
Critch-Gilfillan, Terese
Zhao, Min
Salahuddin, Syim
Gupta, Shaili
Sutton, Richard
Friedland, Gerald
Emu, Brinda
Ogbuagu, Onyema
author_facet Tuan, Jessica J.
Zapata, Heidi
Barakat, Lydia
Andrews, Laurie
Behnegar, Anousheh
Kim, Yee Won
Kayani, Jehanzeb
Mutic, Suzana
Ryall, Linda
Turcotte, Barbara
Critch-Gilfillan, Terese
Zhao, Min
Salahuddin, Syim
Gupta, Shaili
Sutton, Richard
Friedland, Gerald
Emu, Brinda
Ogbuagu, Onyema
author_sort Tuan, Jessica J.
collection PubMed
description BACKGROUND: The durability of immune responses to COVID-19 vaccines among older people living with HIV (PWH) is clinically important. METHODS: We aimed to assess vaccine-induced humoral immunity and durability in older PWH (≥ 55 years, n = 26) over 6 months (post-initial BNT162b2 series). A secondary and exploratory objective was to assess T-cell response and BNT162b2 booster reactogenicity, respectively. Our Visit 1 (3 weeks post-initial BNT162b2 dose) SARS-CoV-2 humoral immunity results are previously reported; these subjects were recruited for Visit 2 [2 weeks (+ 1 week window) post-second vaccination] and Visit 3 [6 months (± 2 week window) post-initial vaccination] in a single-center longitudinal observational study. Twelve participants had paired Visit 2/3 SARS-CoV-2 Anti-Spike IgG data. At Visit 3, SARS-CoV-2 Anti-Spike IgG testing occurred, and 5 subjects underwent T-cell immune response evaluation. Thereafter, subjects were offered BNT162b2 booster (concurrent day outside our study) per US FDA/CDC guidance; reactogenicity was assessed. The primary study outcome was presence of detectable Visit 3 SARS-CoV-2 Anti-Spike-1-RBD IgG levels. Secondary and exploratory outcomes were T-cell immune response and BNT162b2 booster reactogenicity, respectively. Wilcoxon signed-rank tests analyzed median SARS-CoV-2 Anti-Spike IgG 6-month trends. RESULTS: At Visit 3, 26 subjects underwent primary analysis with demographics noted: Median age 61 years; male n = 16 (62%), female n = 10 (38%); Black n = 13 (50%), White n = 13 (50%). Most subjects (n = 20, 77%) had suppressed HIV viremia on antiretroviral therapy, majority (n = 24, 92%) with CD4 > 200 cells/µL. At Visit 3, 26/26 (100%) had detectable Anti-Spike-1-RBD (≥ 0.8 U/mL). Among 12 subjects presenting to Visit 2/3, median SARS-CoV-2 Anti-Spike 1-RBD was 2087 U/mL at Visit 2, falling to 581.5 U/mL at Visit 3 (p = 0.0923), with a median 3.305-fold decrease over 6 months. Among subjects (n = 5) with 6-month T-cell responses measured, all had detectable cytokine-secreting anti-spike CD4 responses; 3 had detectable CD4 + Activation induced marker (AIM) + cells. Two had detectable cytokine-secreting CD8 responses, but all had positive CD8 + AIM + cells. CONCLUSIONS: Among older PWH, SARS-CoV-2 Anti-Spike IgG and virus-specific T-cell responses are present 6 months post-primary BNT162b2 vaccination, and although waning, suggest retention of some degree of long-term protective immunity.
format Online
Article
Text
id pubmed-9491266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94912662022-09-21 Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH) Tuan, Jessica J. Zapata, Heidi Barakat, Lydia Andrews, Laurie Behnegar, Anousheh Kim, Yee Won Kayani, Jehanzeb Mutic, Suzana Ryall, Linda Turcotte, Barbara Critch-Gilfillan, Terese Zhao, Min Salahuddin, Syim Gupta, Shaili Sutton, Richard Friedland, Gerald Emu, Brinda Ogbuagu, Onyema BMC Infect Dis Research BACKGROUND: The durability of immune responses to COVID-19 vaccines among older people living with HIV (PWH) is clinically important. METHODS: We aimed to assess vaccine-induced humoral immunity and durability in older PWH (≥ 55 years, n = 26) over 6 months (post-initial BNT162b2 series). A secondary and exploratory objective was to assess T-cell response and BNT162b2 booster reactogenicity, respectively. Our Visit 1 (3 weeks post-initial BNT162b2 dose) SARS-CoV-2 humoral immunity results are previously reported; these subjects were recruited for Visit 2 [2 weeks (+ 1 week window) post-second vaccination] and Visit 3 [6 months (± 2 week window) post-initial vaccination] in a single-center longitudinal observational study. Twelve participants had paired Visit 2/3 SARS-CoV-2 Anti-Spike IgG data. At Visit 3, SARS-CoV-2 Anti-Spike IgG testing occurred, and 5 subjects underwent T-cell immune response evaluation. Thereafter, subjects were offered BNT162b2 booster (concurrent day outside our study) per US FDA/CDC guidance; reactogenicity was assessed. The primary study outcome was presence of detectable Visit 3 SARS-CoV-2 Anti-Spike-1-RBD IgG levels. Secondary and exploratory outcomes were T-cell immune response and BNT162b2 booster reactogenicity, respectively. Wilcoxon signed-rank tests analyzed median SARS-CoV-2 Anti-Spike IgG 6-month trends. RESULTS: At Visit 3, 26 subjects underwent primary analysis with demographics noted: Median age 61 years; male n = 16 (62%), female n = 10 (38%); Black n = 13 (50%), White n = 13 (50%). Most subjects (n = 20, 77%) had suppressed HIV viremia on antiretroviral therapy, majority (n = 24, 92%) with CD4 > 200 cells/µL. At Visit 3, 26/26 (100%) had detectable Anti-Spike-1-RBD (≥ 0.8 U/mL). Among 12 subjects presenting to Visit 2/3, median SARS-CoV-2 Anti-Spike 1-RBD was 2087 U/mL at Visit 2, falling to 581.5 U/mL at Visit 3 (p = 0.0923), with a median 3.305-fold decrease over 6 months. Among subjects (n = 5) with 6-month T-cell responses measured, all had detectable cytokine-secreting anti-spike CD4 responses; 3 had detectable CD4 + Activation induced marker (AIM) + cells. Two had detectable cytokine-secreting CD8 responses, but all had positive CD8 + AIM + cells. CONCLUSIONS: Among older PWH, SARS-CoV-2 Anti-Spike IgG and virus-specific T-cell responses are present 6 months post-primary BNT162b2 vaccination, and although waning, suggest retention of some degree of long-term protective immunity. BioMed Central 2022-09-21 /pmc/articles/PMC9491266/ /pubmed/36131232 http://dx.doi.org/10.1186/s12879-022-07737-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tuan, Jessica J.
Zapata, Heidi
Barakat, Lydia
Andrews, Laurie
Behnegar, Anousheh
Kim, Yee Won
Kayani, Jehanzeb
Mutic, Suzana
Ryall, Linda
Turcotte, Barbara
Critch-Gilfillan, Terese
Zhao, Min
Salahuddin, Syim
Gupta, Shaili
Sutton, Richard
Friedland, Gerald
Emu, Brinda
Ogbuagu, Onyema
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
title Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
title_full Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
title_fullStr Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
title_full_unstemmed Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
title_short Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
title_sort long-term quantitative assessment of anti-sars-cov-2 spike protein immunogenicity (quasi) after covid-19 vaccination in older people living with hiv (pwh)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491266/
https://www.ncbi.nlm.nih.gov/pubmed/36131232
http://dx.doi.org/10.1186/s12879-022-07737-0
work_keys_str_mv AT tuanjessicaj longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT zapataheidi longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT barakatlydia longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT andrewslaurie longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT behnegaranousheh longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT kimyeewon longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT kayanijehanzeb longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT muticsuzana longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT ryalllinda longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT turcottebarbara longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT critchgilfillanterese longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT zhaomin longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT salahuddinsyim longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT guptashaili longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT suttonrichard longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT friedlandgerald longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT emubrinda longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh
AT ogbuaguonyema longtermquantitativeassessmentofantisarscov2spikeproteinimmunogenicityquasiaftercovid19vaccinationinolderpeoplelivingwithhivpwh